Professor Kev Dhaliwal is a clinician-scientist with a focus on developing technologies that can directly improve patient care. His work sits at the interface of medicine, engineering, and data science, with a particular emphasis on infection and inflammation. As Co-Director of the Baillie Gifford Pandemic Science Hub, he leads programmes aimed at developing new therapies and technologies to address some of the most pressing global health challenges.
Beyond academia and clinical research, Professor Dhaliwal is also actively involved in the technology and innovation ecosystem. As a board director of CodeBase, the UK’s largest technology incubator, he supports the development and scaling of early-stage companies. He advocates for cross-disciplinary collaboration and the translation of physical science research into healthcare.
His work at MicroTex
Within MicroTex, Professor Dhaliwal plays a critical role in ensuring that technological innovation is grounded in clinical reality. A key part of his contribution is ensuring that regulatory and clinical considerations are integrated from the outset, particularly important when developing medical devices and approaches that will be used in humans.
Professor Dhaliwal’s expertise lies in understanding the broader landscape of drug development—where challenges arise, why therapies fail, and what is needed to generate meaningful evidence earlier in the process. By bridging clinical insight, research delivery, and innovation, his work helps ensure that MicroTex is not only developing new technologies, but doing so in a way that can translate effectively into patient benefit.